Siponimod vs Fingolimod — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Sphingosine 1-phosphate Receptor Modulator

Siponimod

Brand: MAYZENT

First FDA approval: 2019-03-26

Sphingosine 1-phosphate Receptor Modulator

Fingolimod

Brand: Fingolimod

First FDA approval: 2010-09-21

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$4.79Per unit

Average NADACAcross all dosage forms and strengths

—

$4.79Up to $4.79

Generic manufacturersActive ANDA holders — FDA Orange Book

13 total ANDAs filed

1414 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$114.1MFull year

$155.1MFull year

Part D claims (CY24)Total fills, all strengths

10K2K beneficiaries

48K8K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$11,236Per claim, all NDCs

$3,233Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

444Substantial friction

259Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes1 manufacturers

Yes14 manufacturers